Format

Send to

Choose Destination
Neuroscience. 2018 Feb 10;371:337-345. doi: 10.1016/j.neuroscience.2017.11.044. Epub 2017 Dec 2.

Effects on Hedonic Feeding, Energy Expenditure and Balance of the Non-opioid Peptide DYN-A2-17.

Author information

1
Center for Integrative Medicine and Innovative Science, Facultad de Medicina, Universidad Andres Bello, Santiago, Región Metropolitana 8370071, Chile.
2
Department of Nutritional Sciences, University of Arizona, Tucson, AZ 85721, USA; Minneapolis VA Health Care System, Minneapolis, MN 55417, USA; Minnesota Obesity Center, University of Minnesota, Saint Paul, MN 55108, USA; Department of Food Science and Nutrition, University of Minnesota, Saint Paul, MN 55108, USA.
3
Center for Integrative Medicine and Innovative Science, Facultad de Medicina, Universidad Andres Bello, Santiago, Región Metropolitana 8370071, Chile; Department of Food Science and Nutrition, University of Minnesota, Saint Paul, MN 55108, USA. Electronic address: claudio.perez@unab.cl.

Abstract

The dynorphin (DYN) peptide family includes opioid and non-opioid peptides, yet the physiological role of the non-opioid DYN peptides remains poorly understood. Recent evidence shows that administering the non-opioid peptide DYN-A2-17 into the paraventricular hypothalamic nucleus (PVN) simultaneously increased short-term intake of standard rodent chow and spontaneous physical activity (SPA). The present studies aimed to expand upon the mechanisms and role of DYN-A2-17 on food intake and energy expenditure. Injection of DYN-A2-17 in PVN increased SPA, energy expenditure and wheel running in the absence of food. Repeated DYN-A2-17 injection in PVN increased short-term chow intake, but this effect habituated over time and failed to alter cumulative food intake, body weight or adiposity. Pre-treatment with a CRF receptor antagonist into PVN blocked the effects of DYN-A2-17 on food intake while injection of DYN-A2-17 in PVN increased plasma ACTH. Finally, as DYN peptides are co-released with orexin peptides, we compared the effects of DYN-A2-17 to orexin-A and the opioid peptide DYN-A1-13 on food choice and intake in PVN when palatable snacks and chow were available. DYN-A1-13 selectively increased intake of palatable snacks. DYN-A2-17 and orexin-A decreased palatable snack intake while orexin-A also increased chow intake. These findings demonstrate that the non-opioid peptide DYN-A2-17 acutely regulates physical activity, energy expenditure and food intake without long-term effects on energy balance. These data also propose different roles of opioid, non-opioid DYN and orexin peptides on food choice and intake when palatable and non-palatable food options are available.

KEYWORDS:

dynorphin; energy expenditure; exercise; food intake; hedonic food intake; orexin

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center